Xenon Pharmaceuticals (XENE) Tops Q2 EPS by 24c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 6, 2020 4:02 PM EDTXEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020
Conference Call at 4:30 pm ET Today
BURNABY, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported its financial results for second quarter ended June 30, 2020 and provided a corporate update.
Dr. Simon Pimstone, Xenons Chief Executive Officer, said, Xenon continues to manage well as we respond to the global impacts of the COVID-19... More
